Oculis (NASDAQ:OCS) Sets New 12-Month High – What’s Next?

Oculis Holding AG (NASDAQ:OCS)’s stock price reached a new 52-week high on Monday . The company traded as high as $18.10 and last traded at $17.57, with a volume of 58391 shares traded. The stock had previously closed at $17.56.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on OCS. Chardan Capital reiterated a “buy” rating and issued a $28.00 price target on shares of Oculis in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Oculis in a report on Monday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $28.80.

Oculis Stock Up 3.2 %

The firm has a market capitalization of $737.98 million, a PE ratio of -9.44 and a beta of -0.33. The firm’s 50-day moving average is $16.35 and its 200 day moving average is $13.84. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.